Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804).
2011 ◽
Vol 29
(15_suppl)
◽
pp. LBA7511-LBA7511
◽
Keyword(s):
2011 ◽
Vol 47
◽
pp. S622-S623
◽
Keyword(s):
2015 ◽
Vol 10
(4)
◽
pp. 655-664
◽
Keyword(s):
2007 ◽
Vol 5
(6)
◽
pp. 2
◽
Keyword(s):
2020 ◽
Vol 17
(21)
◽
pp. 7995
Keyword(s):
2007 ◽
Vol 2
(8)
◽
pp. S375
◽
Keyword(s):
Keyword(s):
2020 ◽
Vol 108
(3)
◽
pp. S105
2015 ◽
Keyword(s):
Keyword(s):